BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite
broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated …

INTRODUCTION: Many options are available for patients with moderate to severe plaque
psoriasis. Patients with moderate disease, however, are often undertreated and do not …

Background Patients with mild-to-moderate psoriasis may have substantial quality-of-life
impairment. Objective To evaluate apremilast 30 mg twice daily for mild-to-moderate …

Background Randomized, controlled trials demonstrated efficacy and safety of apremilast for
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …

Background: Apremilast is a new oral drug for the treatment of moderate to severe plaque
psoriasis that reduces inflammation by inhibiting phosphodiesterase 4. Its efficacy and safety …

OBJECTIVE: To examine real-world use and patient outcomes with apremilast, an oral
PDE4 inhibitor, in the dermatology practice set-ting for treatment of patients with moderate to …

Background Pharmacodynamic (PD) subanalyses of clinical trials in patients with moderate
to severe psoriasis demonstrated the efficacy of apremilast correlated with reductions in …

Apremilast is a small molecule approved for the treatment of plaques psoriasis and adult
psoriatic arthritis. Pivotal studies have demonstrated short and long term efficacy and safety …

Background Apremilast, an oral, small‐molecule phosphodiesterase 4 inhibitor, has
demonstrated efficacy in patients with moderate‐to‐severe psoriasis. Objective Evaluate …

Background: Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor used for the
treatment of moderate to severe psoriasis. Long-term data on the effectiveness and drug …